Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

82.11 +1.92 (+2.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
Via The Motley Fool
AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients
AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority Review expected in Q2 2025. 
Via Benzinga
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
Is NASDAQ:AZN suited for quality investing?
A fundamental analysis of (NASDAQ:AZN): Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) a Strong Candidate for Quality Investing? 
Via Chartmill
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
Why AstraZeneca Topped the Market on Thursday
Via The Motley Fool
AstraZeneca Unusual Options Activity
 
Via Benzinga
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
From Faruqi & Faruqi LLP
Via GlobeNewswire
Trade Desk, Leidos, Devon Energy And A Major Health Care Stock On CNBC's 'Final Trades'
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Earnings Scheduled For February 6, 2025
 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IIPR, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript
AZN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
AstraZeneca Bounds Higher On Fourth-Quarter Beat, Upbeat Guidance
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance. 
Via Investor's Business Daily
AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
AstraZeneca's Q4 revenue beat estimates at $14.89 billion, with strong oncology sales. China sales dipped 1%, while FY25 guidance forecasts solid growth. 
Via Benzinga
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
AstraZeneca’s Full Year and Q4 2024 results
From AstraZeneca
Via Business Wire
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Q4 Earnings Scorecard & Analyst Reports For Alphabet, Blackstone & KLA
Today's Research Daily features a real-time scorecard of the Q4 earnings season and new research reports on 16 major stocks, including Alphabet Inc., Blackstone Inc., and KLA Corporation, as well as a... 
Via Talk Markets
Topics Stocks / Equities
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant
AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing concerns over NHS drug pricing and industry tensions. 
Via Benzinga
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, IIPR, Block, and Crocs and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
From Faruqi & Faruqi LLP
Via GlobeNewswire
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback